(Q24799636)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Misleading funnel plot for detection of bias in meta-analysis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

The number needed to treat: a clinically useful measure of treatment effect

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

The importance of quality of primary studies in producing unbiased systematic reviews

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Using numerical results from systematic reviews in clinical practice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Confidence intervals rather than P values: estimation rather than hypothesis testing

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=32301

Treatment of genital warts with an immune-response modifier (imiquimod).

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-1-3

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-1-3

A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-1-3

Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-1-3

Reporting of Adverse Effects in Clinical Trials Should Be Improved

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-1-3

1998 guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11401728

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

National guideline for the management of anogenital warts. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11401728

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

New cases seen at genitourinary medicine clinics: England 1998

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11401728

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2334-1-3

1 reference

Dimensions Publication ID

3723776

1000544032

0 references

3723776

1 reference

1 reference

1 reference